Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R F Tyndale

Showing results (11-20 of 88) with videos related to

Pageof 9
Sort By:
Clinical Pharmacology and Therapeutics|February 18, 2011
Pharmacogenomics at the tipping point: challenges and opportunitiesD M Roden, R F Tyndale
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 1, 1994
Few cell lines with GABAA mRNAs have functional receptorsT G Hales, R F Tyndale
Clinical Pharmacology and Therapeutics|January 14, 2017
Designer Drugs 2.0M A Huestis, R F Tyndale
Clinical Pharmacology and Therapeutics|March 25, 2015
Cannabinoids: Friend or foe?B Le Foll, R F Tyndale
Biochemical Pharmacology|May 9, 2000
Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatmentS Miksys, E Hoffmann, R F Tyndale
British Journal of Clinical Pharmacology|June 1, 1991
Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase)R F Tyndale, W Kalow, T Inaba
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1989
Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitroR F Tyndale, T Inaba, W Kalow
Clinical Pharmacology and Therapeutics|January 21, 2012
Twenty-first-century neuroscience: the potential for innovative therapies for brain disordersS L Miksys, K Uhl, R F Tyndale
Pharmacogenetics|August 16, 2001
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substratesY Ramamoorthy, R F Tyndale, E M Sellers
Clinical Pharmacology and Therapeutics|August 17, 2000
Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smokingE M Sellers, H L Kaplan, R F Tyndale
Pageof 9

Showing results (11-20 of 88) with videos related to

Sort By:
Pageof 9
Clinical Pharmacology and Therapeutics|February 18, 2011
Pharmacogenomics at the tipping point: challenges and opportunitiesD M Roden, R F Tyndale
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 1, 1994
Few cell lines with GABAA mRNAs have functional receptorsT G Hales, R F Tyndale
Clinical Pharmacology and Therapeutics|January 14, 2017
Designer Drugs 2.0M A Huestis, R F Tyndale
Clinical Pharmacology and Therapeutics|March 25, 2015
Cannabinoids: Friend or foe?B Le Foll, R F Tyndale
Biochemical Pharmacology|May 9, 2000
Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatmentS Miksys, E Hoffmann, R F Tyndale
British Journal of Clinical Pharmacology|June 1, 1991
Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase)R F Tyndale, W Kalow, T Inaba
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1989
Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitroR F Tyndale, T Inaba, W Kalow
Clinical Pharmacology and Therapeutics|January 21, 2012
Twenty-first-century neuroscience: the potential for innovative therapies for brain disordersS L Miksys, K Uhl, R F Tyndale
Pharmacogenetics|August 16, 2001
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substratesY Ramamoorthy, R F Tyndale, E M Sellers
Clinical Pharmacology and Therapeutics|August 17, 2000
Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smokingE M Sellers, H L Kaplan, R F Tyndale
Pageof 9